Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy
ESMO 2018 CongressCora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-025 study on nivolumab vs everolimus for mRCC; the CheckMate-214 study on nivolumab, ipilimumab, and sunitinib for treatment-naive advanced or metastatic clear-cell RCC; and immunotherapy for urothelial cancer for both first- line cisplatin-ineligible and second-line therapy after cisplatin chemotherapy.
Related Videos
Ezra E.W. Cohen, MD, on Head and Neck Cancer: Using Curative Immunotherapy
Ezra E.W. Cohen, MD, of the University of California, San Diego, discusses the effectiveness of anti–PD-1 therapy in patients with recurrent head and neck cancer and the stud...
Matti S. Aapro, MD, on Immunotherapy in Older Patients
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining...
Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy
Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women w...
Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective
Martin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations an...
Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib a...
